Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aerovate Therapeutics, Inc. - Common Stock (NQ: AVTE )

2.470 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aerovate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday. Shares of Ermenegildo Zegna N.V. (NYSE: ZGN) fell sharply during Friday’s session as the company reported FY23... 
Via Benzinga
Topics Stocks
Exposures US Equities
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Recap: Aerovate Therapeutics Q4 Earnings
Via Benzinga
Recap: Aerovate Therapeutics Q3 Earnings
Via Benzinga
Recap: Aerovate Therapeutics Q1 Earnings
Via Benzinga
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
10 Short Squeeze Candidates: Getty Images, Genius Brands, MicroStrategy And More
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits... 
Via Benzinga
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Ambrx Biopharma, PaxMedica And 3 More Short Squeeze Stocks That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued to attract attention, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the... 
Via Benzinga
Singing Machine, Blue Apron, Camber Energy And More Short Squeeze Candidates That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common... 
Via Benzinga
Singing Machine, SurgePays And 3 More Short Squeeze Stocks That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common... 
Via Benzinga
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Dow Jumps 600 Points; US Inflation Rate Slows In November
U.S. stocks traded higher this morning, with the Dow Jones gaining over 600 points on Tuesday 
Via Benzinga
Bitcoin Holder MicroStrategy, SurgePays And 3 Other Short Squeeze Stocks That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common... 
Via Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis
Via Benzinga
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.